FDA Grants Full Approval to Lecanemab for the Treatment of Alzheimer’s On July 6, the Food and Drug Administration granted full approval to LEQEMBI (lecanemab) for the treatment of Alzheimer’s disease (AD). According to the current FDA approval, lecanemab should be initiated in patients with mild cognitive impairment or mild dementia. Lecanemab is the first approved treatment shown to slow down the progression of the disease, reduce cognitive decline, and improve daily functioning in adults with AD.
